21st Century Tools for Pain and Addiction Treatment Act

Bill: 115-hr-5806
Sponsor: full_name: Rep. Burgess, Michael C. [R-TX-26]
Introduced: 2018-05-15
Policy area: Health
Subjects: Administrative law and regulatory procedures

Department of Health and Human Services

Drug safety, medical device, and laboratory regulation

Drug therapy

Drug trafficking and controlled substances

Drug, alcohol, tobacco use

Food and Drug Administration (FDA)

Public participation and lobbying
Latest action: action_date: 2018-05-17
text: Ordered to be Reported by the Yeas and Nays: 31 - 23.

Summaries:
action_date: 2018-05-15
action_desc: Introduced in House
text: <p><b>21st Century Tools for Pain and Addiction Treatment Act</b></p> <p>This bill requires the Food and Drug Administration (FDA)to revise how it will address the challenges and barriers of developing non-addictive medical products to treat pain or addiction. </p>

tv_txt: I 115th CONGRESS 2d Session H. R. 5806 IN THE HOUSE OF REPRESENTATIVES May 15, 2018 Mr. Burgess (for himself, Mr. Bucshon , and Mr. Griffith ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To require the Secretary of Health and Human Services to issue guidance with respect to the expedited approval of certain drugs, and for other purposes.

1. Short title This Act may be cited as the 21st Century Tools for Pain and Addiction Treatment Act . 2. Clarifying FDA regulation of non-addictive pain and addiction therapies (a) Public meetings Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall hold not less than one public meeting to address the challenges and barriers of developing non-addictive medical products intended to treat pain or addiction, which may include— (1) the application of novel clinical trial designs (consistent with section 3021 of the 21st Century Cures Act ( Public Law 114–255 )), use of real world evidence (consistent with section 505F of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355g )), and use of patient experience data (consistent with section 569C of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–8c )) for the development of non-addictive medical products intended to treat pain or addiction; and (2) the application of eligibility criteria under sections 506 and 515B of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356 , 360e–3) for non-addictive medical products intended to treat pain or addiction. (b) Guidance Not later than one year after the public meetings are conducted under subsection (a) the Secretary shall issue one or more final guidance documents, or update existing guidance documents, to help address challenges to developing non-addictive medical products to treat pain or addiction. Such guidance documents shall include information regarding— (1) how the Food and Drug Administration may apply sections 506 and 515B of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356 , 360e–3) to non-addictive medical products intended to treat pain or addiction, including the circumstances under which the Secretary— (A) may apply the eligibility criteria under such sections 506 and 515B to non-opioid or non-addictive medical products intended to treat pain or addiction; (B) considers the risk of addiction of controlled substances approved to treat pain when establishing unmet medical need; and (C) considers pain, pain control, or pain management in assessing whether a disease or condition is a serious or life-threatening disease or condition; and (2) the methods by which sponsors may evaluate acute and chronic pain, endpoints for non-addictive medical products intended to treat pain, the manner in which endpoints and evaluations of efficacy will be applied across and within review divisions, taking into consideration the etiology of the underlying disease, and the manner in which sponsors may use surrogate endpoints, intermediate endpoints, and real world evidence. (c) Medical product defined In this section, the term medical product means a drug (as defined in section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321(g)(1) )), biological product (as defined in section 351(i) of the Public Health Service Act ( 42 U.S.C. 262(i) )), or device (as defined in section 201(h) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321(h) )).